Sociedad Americana de Hirudoterapia

Pharmaceutical Society of Jamaica — Pharmacy Council of Jamaica

PCJ · Jamaica · latin america

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Jamaica's Pharmacy Council (statutory regulator of pharmacy practice, in coordination with the Ministry of Health and Wellness) — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
latin america
Country
Jamaica
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Jamaican Food and Drugs Act
  • Pharmacy Act of Jamaica
  • Jamaican national medical device regulatory framework

Prescriber Requirements

  • Medical Council of Jamaica–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Ministry of Health and Wellness registration as applicable; English-language labelling. Standard cold-chain conditions.

Import/Export Rules

Ministry of Health and Wellness import authorisation; Veterinary Services Division clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Caribbean states often share elements of regulatory practice via CARPHA (Caribbean Public Health Agency) and CARICOM harmonisation; the exact mechanism for live-organism medical devices has not been independently mapped by ASH. Region assigned as latin-america for coverage purposes pending Caribbean sub-region implementation.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.